Merck KGaA and Novo Nordisk are realigning their access-related targets and access initiatives with the Sustainable Development Goals (SDGs).
Gilead and Bristol-Myers Squibb take the first moves, from companies in scope of the Access to Medicine Index 2016, outside non-exclusive voluntary licensing in HIV/AIDS.
AstraZeneca has a new pricing policy for its respiratory and cardiovascular disease products in certain key out-of-pocket markets in scope, based on an ability-to-pay analysis.
Bayer co-founded an International Society of Pharmacovigilance Special Interest Group to develop and share innovative risk minimisation methods and tools.
AstraZeneca has developed an internal governance structure for its Healthy Heart Africa programme, consisting of a Global Advisory Board and National Steering Committee.
The Financial, Environmental and Social Profit and Loss (FES P&L) approach aims to measure the social and economic impact of Novartis’ social activities on local communities.
Nine companies have committed to R&D for antimicrobial resistance (AMR), signing the Davos Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance.